FDA Approves EPIPEN — Viatris Specialty LLC

Viatris Specialty LLC secured FDA approval for its epinephrine injectable product, expanding the availability of generic alternatives to the branded EpiPen. This regulatory clearance is expected to intensify market competition in the anaphylaxis treatment sector and drive potential cost efficiencies for both providers and patients.